Actively Recruiting
Establishment of Primary Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer for Preclinical Evaluation of Targeted Therapies.
Led by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Updated on 2024-12-03
40
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting fresh tumor tissue from patients with head and neck cancer, either primary or recurrent, to develop patient-derived xenografts. These models represent different tumor subgroups and will be used to study the genetics and behavior of the tumors, including their response to new targeted therapies and resistance patterns. The study aims to create a biobank to support preclinical evaluation of treatments for head and neck cancer. Patients will undergo a tumor biopsy of at least 0.5 cm2 during surgery or endoscopy if there is enough tissue available and after their consent. The collected tumor samples will be used to establish in vivo xenograft models. This observational study does not involve experimental treatments but focuses on tissue collection and laboratory analysis over a long-term period. Participants' clinical data including stage, grade, and treatment history will be gathered, along with follow-up information. Researchers will analyze tumor samples using genetic profiling and immunohistochemistry to identify biomarkers related to drug sensitivity and treatment resistance. The primary outcome involves biomarker identification on tumor samples over 10 years, with ongoing characterization using genetic techniques. This long-term observation supports future cancer therapy development and assessment.
CONDITIONS
Brief Title
Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with primary or recurrent/metastatic head and neck cancer can be included pre-operatively or before a tumor biopsy
- Data on cancer stage, grade, histology, adjuvant treatment, responses, and relapse must be available
- Follow-up data must be available
- Patients with recurrent disease are allowed
- Written informed consent is required
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo a tumor biopsy during surgery or endoscopy if eligible and consented.
1 visit (in-person)
Duration - Up to 10 years
Participants are observed over time with data collected on cancer stage, treatment responses, and relapse.
Periodic follow-up visits as part of routine care
Trial Site Locations
Total: 1 location
1
Cliniques universitaires Saint-Luc
Brussels, Belgium, 1200
Actively Recruiting
Research Team
A
Aline Gillain, MedSciences
S
Sandra Schmitz, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here